PROGRAM CHAIR
Neil M. Bressler, MD
The James P. Gills Professor of Ophthalmology
Retina Division (Chief: 2005-2018) – Wilmer Eye Institute
Johns Hopkins University School of Medicine & Hospital
Baltimore, MD
Participation by Dr. Neil Bressler in this activity does not constitute or imply endorsement by the Johns Hopkins University, the Johns Hopkins Hospital, the Johns Hopkins Health System, the Jaeb Center for Health Research Foundation, Inc., the FDA, the NIH, the AMA, nor JAMA Ophthalmology
This presentation, including any recordings of it, is solely for the use of this CME program, and may contain privileged, confidential or proprietary information, and may not be redistributed in any way without the consent of the author and Med Learning Group. Some copyright © 2024 Johns Hopkins University.
All Rights Reserved, including those for text and data mining, AI training, and similar technologies.
FACULTY
Susan B. Bressler, MD
Professor of Ophthalmology
Johns Hopkins University School of Medicine
Julia G. Levy PhD Professor of Ophthalmology, Wilmer Eye Institute
Johns Hopkins University
Baltimore, MD
Participation by Dr. Susan Bressler in this activity does not constitute or imply endorsement by the Johns Hopkins University, the Johns Hopkins Hospital, or the Johns Hopkins Health System.
This presentation, including any recordings of it, is solely for the use of this CME program, and may contain privileged, confidential or proprietary information, and may not be redistributed in any way without the consent of the author and Med Learning Group. Some copyright © 2024 Johns Hopkins University.
All Rights Reserved, including those for text and data mining, AI training, and similar technologies.
PROGRAM OVERVIEW
This enduring activity will address the burdens associated with treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) that can contribute to poorer vision outcomes in patients. Group case-study discussions are used to provide retina specialists and comprehensive ophthalmologists with knowledge and tactics to address treatment barriers with anti-VEGF therapy. Using individualized approaches to treatment, such as dosing strategies and use of next-generation anti-VEGF therapy, and a panel discussion to enhance the practical integration of addressing treatment burden, you will be equipped with the knowledge and tactics to optimize your patients’ outcomes.
TARGET AUDIENCE
This initiative is designed to meet the educational needs of retina specialists, comprehensive ophthalmologists, and retina fellows involved in the management of patients with retinal vascular disease.
LEARNING OBJECTIVES
- Evaluate adherence barriers in nAMD and DME treatment, including injection frequency and patient factors
- Analyze the duration of effectiveness in established and emerging therapies for nAMD and DME
- Identify patients eligible for dosing modifications or transitioning to longer-lasting therapies, based on individual, treatment, and disease considerations
- Personalize treatment selection and dosing strategies to optimize care for nAMD and DME patients
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.25 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Neil M. Bressler, MD, discloses the following: | Disclosures |
| AMA – JAMA Ophthalmology* Editor-in-Chief | Contract from AMA** |
| Bayer Healthcare Pharmaceuticals Inc. | Grant Support to JHU** |
| Boehringer Ingelheim | Prior Grant support to JHU** |
| FDA: Chair, Ophthalmic Devices Panel | Honorarium from FDA** |
| Genentech (Roche) | Prior Grant Support to JHU** |
| Jaeb Center for Health Research Foundation, Inc. | Voluntary: Board of Directors |
| Regeneron | Grant Support to JHU** |
| Samsung Bioepis | Prior Grant Support to JHU** |
| EMMES Company, LLC – Chair: Data and Safety Monitoring Committee for The National Eye Institute Intramural Program | Contract from EMMES Company, LLC |
| *Participation by Dr. Neil Bressler in this activity does not constitute or imply endorsement by the Johns Hopkins University, the Johns Hopkins Hospital, the Johns Hopkins Health System, the Jaeb Center for Health Research Foundation, Inc., the FDA, the NIH, the AMA, nor JAMA Ophthalmology | **AMA = American Medical Association; FDA = Food and Drug Administration; JHU = Johns Hopkins University School of Medicine |
| Susan B. Bressler, MD discloses the following: | Disclosures |
| Bayer | Consultant |
| Boehringer-Ingelheim, Genentech, Regeneron Pharmaceuticals, Inc., Bayer, Mylan-Viatris, Biocon, Biogen, Bausch and Lomb | Contracted Research |
| Amgen | Chair of DMSC |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
- Sharon Windsor Harker, Medical Director of Med Learning Group, has nothing to disclose.
- Nicole Longo, DO, FACOI, VP of Med/Sci Services and Learner Engagement of Med Learning Group, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Brianna Hefele, PA-C has nothing to disclose.
- Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
- Kristen Marks, Program Coordinator of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
- Daniel DaSilva, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: January 10, 2025
EXPIRATION DATE: January 10, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
